Phase 2 Non-Alcoholic Fatty Liver Disease Trial, Recruiting NCT06133101 Sponsor: Marialena Mouzaki Condition: Non-Alcoholic Fatty Liver Disease
Back to Non Alcoholic Fatty Liver Disease

Phase 2 Non-Alcoholic Fatty Liver Disease Trial, Recruiting

NCT06133101
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Children who are overweight or obese
  • Children who have a liver condition called non-alcoholic fatty liver disease (NAFLD), confirmed by a specific MRI scan showing fat in the liver above 10%
  • Children who have either a known diagnosis of NAFLD or elevated liver enzyme levels (a blood test result above a certain level, which differs slightly between males and females)

Who may not be able to join:

  • Children whose MRI scan shows liver fat at or below 10%
  • Children who already regularly eat soy-based foods more than 3 days per week
  • Children who have an allergy to soy or cow's milk protein
  • Children who are unable to have an MRI scan
  • Children who have taken antibiotics in the past 8 weeks
  • Children who are currently receiving treatment for a hormonal (endocrine) condition

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: (513) 636-8867

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Marialena Mouzaki
Registry
ClinicalTrials.gov
Start date
15 January 2024
Est. completion
1 March 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in liver disease severity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov